Research Papers: Gerotarget (Focus on Aging):
New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor
Metrics: PDF 2069 views | HTML 3195 views | ?
Abstract
Rosemeire M. Kanashiro-Takeuchi1,2,*, Luca Szalontay3,*, Andrew V. Schally1,3,4,5,6, Lauro M. Takeuchi1, Petra Popovics3,7,8, Miklos Jaszberenyi3,4, Irving Vidaurre3, Marta Zarandi3, Ren-Zhi Cai3,4, Norman L. Block1,3,4,5,6, Joshua M. Hare1,8, Ferenc G. Rick3,9
1Interdisciplinary Stem Cell Institute, University of Miami, Miller School of Medicine, Miami, Florida, United States of America
2Department of Molecular and Cellular Pharmacology, University of Miami, Miller School of Medicine, Florida, United States of America
3Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, Florida, United States of America
4Department of Pathology, University of Miami, Miller School of Medicine, Miami, Florida, United States of America
5Department of Medicine, Divisions of Hematology/Oncology and Endocrinology, University of Miami, Miller School of Medicine, Miami, Florida, United States of America
6Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, United States of America
7Department of Medicine III, Medical Faculty Carl Gustav Carus, TU Dresden, Germany
8Department of Medicine, Division of Cardiology, University of Miami, Miller School of Medicine, Miami, Florida, United States of America
9Department of Urology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, United States of America
*These authors have contributed equally to this work
Correspondence to:
Ferenc G. Rick, e-mail: [email protected]
Keywords: growth hormone-releasing hormone, myocardial infarction, heart failure, remodeling, cardioprotection
Received: January 27, 2015 Accepted: February 08, 2015 Published: March 14, 2015
ABSTRACT
Background: We previously showed that growth hormone-releasing hormone (GHRH) agonists are cardioprotective following myocardial infarction (MI). Here, our aim was to evaluate the in vitro and in vivo activities of highly potent new GHRH agonists, and elucidate their mechanisms of action in promoting cardiac repair.
Methods and Results: H9c2 cells were cultured in serum-free medium, mimicking nutritional deprivation. GHRH agonists decreased calcium influx and significantly improved cell survival. Rats with cardiac infarction were treated with GHRH agonists or placebo for four weeks. MI size was reduced by selected GHRH agonists (JI-38, MR-356, MR-409); this accompanied an increased number of cardiac c-kit+ cells, cellular mitotic divisions, and vascular density. One week post-MI, MR-409 significantly reduced plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo. Gene expression studies revealed favorable outcomes of MR-409 treatment partially result from inhibitory activity on pro-apoptotic molecules and pro-fibrotic systems, and by elevation of bone morphogenetic proteins.
Conclusions: Treatment with GHRH agonists appears to reduce the inflammatory responses post-MI and may consequently improve mechanisms of healing and cardiac remodeling by regulating pathways involved in fibrosis, apoptosis and cardiac repair. Patients with cardiac dysfunction could benefit from treatment with novel GHRH agonists.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3303